Observational studyArthritis research & therapy2022
Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study.
Observational study in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02012764 (The CCP Study), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-clinical Stage ?
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Rheumatoid Arthritis referral criteria: systematic review of the literature.BMC rheumatology · 2026Pooled it
- A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- How do general practitioners diagnose and refer potential rheumatic musculoskeletal complaints? A scoping review.Clinical rheumatology · 2026Article
- First Contact Physiotherapists (FCPs) Referral Practices to Rheumatology: A Scoping Review of the Evidence Base.Musculoskeletal care · 2026Article
- Development and validation of a clinical risk prediction rule to identify inflammatory arthritis at the point of rheumatology triage.Rheumatology advances in practice · 2026Article
- Living with palindromic rheumatism: a qualitative interview study.Rheumatology advances in practice · 2026Article
- Targeted anti-CCP testing to identify people at risk of rheumatoid arthritis in primary care: an early economic evaluation.Rheumatology advances in practice · 2026Article
- Identifying people at risk of rheumatoid arthritis in primary care: a qualitative study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- The journey of patients with musculoskeletal complaints in Europe: a cross-sectional European survey.Rheumatology international · 2025Article
- Ultrasound in anti-CCP+ at-risk individuals without clinical synovitis: development of a novel 6-joint protocol for feasible risk prediction.Rheumatology (Oxford, England) · 2024Article
- Management of Rheumatoid Arthritis in Primary Care: A Scoping Review.International journal of environmental research and public health · 2024Article
- Article
- Opportunities and challenges in early diagnosis of rheumatoid arthritis in general practice.The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Article
- Antibodies to leukotoxin A from the periodontal pathogenFrontiers in medicine · 2023Article
- Modifiable risk factors linked to the development of rheumatoid arthritis: evidence, immunological mechanisms and prevention.Frontiers in immunology · 2023Review
- Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals.RMD open · 2022Article
- Antibodies to Citrullinated Protein Antigens, Rheumatoid Factor Isotypes and the Shared Epitope and the Near-Term Development of Clinically-Apparent Rheumatoid Arthritis.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundMusculoskeletal (MSK) symptoms are among the commonest reasons for primary care assessments; however, few individuals will be diagnosed with an inflammatory arthritis (IA) within the following year. The purpose of this study was to investigate, in individuals with new MSK symptoms, the association between patient factors and risk of progression to IA, in order to optimise primary care referrals to rheumatology.
methodsIndividuals ≥16 years old with new non-specific MSK symptoms and no clinical synovitis were recruited by primary care across the UK from July 2007 until May 2019. Those testing positive for the anti-CCP2 assay (anti-CCP+) were invited to Leeds for follow-up. Subjects with a negative result (anti-CCP-) were sent a 1-year questionnaire, and general practitioners were contacted to confirm whether the individual had been diagnosed with an IA by a rheumatologist. Predictors for progression were assessed using multivariable regression analysis.
resultsSix thousand seven hundred eighty individuals were recruited: 3% were anti-CCP+, of whom 45% progressed to IA, predominantly rheumatoid arthritis. Anti-CCP+ participants with high antibody levels had an odds ratio (OR) for progression to IA of 9.42 [P < 0.001, 95% CI (3.13-28.30)], hand pain, OR 2.74 [P = 0.043, 95% CI (1.03-7.27)] and foot pain, OR 4.10 [P = 0.003, 95% CI (1.59-10.54)]. In low-level anti-CCP+ individuals, absence of pain in hands or feet had a negative predictive value of 96% for progression to IA. One-year follow-up data were available for 5640 anti-CCP- individuals, of whom 53 were diagnosed with IA (0.93%). Pain in hands, OR 2.51 [P = 0.018, 95% CI (1.17-5.39)] or knees, OR 3.03 [P = 0.003, 95% CI (1.47-6.25)] were associated with development of IA within 12 months.
conclusionsThis is the largest prospective primary care study of individuals at risk of IA, and the first one to prospectively investigate the outcome of MSK symptoms in a large anti-CCP- cohort. High anti-CCP levels and pain in hands/feet indicated an increased likelihood of progression to IA. In patients with low anti-CCP level and no pain in the hands/feet, progression is unlikely. In anti-CCP- patients, those with hand or knee pain were at increased risk of progression. This study demonstrates that routinely available tests and joint symptoms provide useful discrimination that may be used to prioritise referrals to rheumatology and avoid a delayed diagnosis.
trial registrationNCT, NCT02012764 . Registered 25 January 2007.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.